Paclitaxel-Based Therapies for Patients With Peripheral Artery Disease.
作者信息
Misra Sanjay, Dake Michael D
机构信息
Mayo Clinic Rochester, Department of Radiology, MN (S.M.).
Health Sciences, The University of Arizona, Tucson (M.D.D.).
出版信息
Circulation. 2019 Mar 26;139(13):1565-1567. doi: 10.1161/CIRCULATIONAHA.118.039510.
Abstract
摘要
相似文献
1
Paclitaxel-Based Therapies for Patients With Peripheral Artery Disease.基于紫杉醇的外周动脉疾病患者治疗方法
Circulation. 2019 Mar 26;139(13):1565-1567. doi: 10.1161/CIRCULATIONAHA.118.039510.
2
Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.用于治疗股腘动脉狭窄的紫杉醇洗脱支架：聚焦于Zilver PTX药物洗脱外周支架
Expert Rev Med Devices. 2015 Mar;12(2):157-62. doi: 10.1586/17434440.2015.985653. Epub 2014 Nov 24.
3
Local delivery of paclitaxel in the treatment of peripheral arterial disease.局部递送紫杉醇治疗外周动脉疾病。
Eur J Clin Invest. 2015 Mar;45(3):333-45. doi: 10.1111/eci.12407. Epub 2015 Feb 14.
4
Local paclitaxel delivery for treatment of peripheral arterial disease.
Circ Cardiovasc Interv. 2011 Jun;4(3):297-302. doi: 10.1161/CIRCINTERVENTIONS.110.961052. Epub 2011 May 3.
5
Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.紫杉醇洗脱球囊与标准球囊血管成形术治疗股浅动脉和腘动脉支架内再狭窄：PACUBA 试验 1 年结果。
JACC Cardiovasc Interv. 2016 Jul 11;9(13):1386-92. doi: 10.1016/j.jcin.2016.04.012.
6
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.紫杉醇涂层 Zilver PTX 药物洗脱支架治疗与未涂层器械相比，不会增加长期全因死亡率。
Cardiovasc Intervent Radiol. 2020 Jan;43(1):8-19. doi: 10.1007/s00270-019-02324-4. Epub 2019 Sep 9.
7
Zilver PTX peripheral paclitaxel-eluting stent: a technology evaluation.Zilver PTX 外周紫杉醇洗脱支架：技术评估。
Expert Opin Drug Deliv. 2020 Oct;17(10):1335-1343. doi: 10.1080/17425247.2020.1789586. Epub 2020 Jul 3.
8
Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?紫杉醇涂层球囊和药物洗脱支架：外周动脉疾病患者的死亡率存在风险吗？
Circulation. 2019 Oct 15;140(16):1342-1351. doi: 10.1161/CIRCULATIONAHA.119.041099. Epub 2019 Jun 10.
9
Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.采用紫杉醇洗脱技术治疗的外周动脉闭塞性疾病患者长段股腘动脉病变的原发性通畅率
Ann Vasc Surg. 2020 Jul;66:595-600. doi: 10.1016/j.avsg.2019.11.044. Epub 2019 Dec 18.
10
Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.外周动脉疾病中的紫杉醇药物洗脱支架：一项卫生技术评估。
Ont Health Technol Assess Ser. 2015 Nov 1;15(20):1-62. eCollection 2015.
引用本文的文献
1
What are the Pathological Concerns and Limitations of Current Drug-coated Balloon Technology?当前药物涂层球囊技术的病理问题及局限性有哪些？
Heart Int. 2019 Oct 11;13(1):15-22. doi: 10.17925/HI.2019.13.1.15. eCollection 2019.
2
Bindarit encapsulated nanoparticles prevent venous neointimal hyperplasia and restenosis in a murine angioplasty model.包裹了本尼达特的纳米粒可预防小鼠血管成形术后静脉内膜增生和再狭窄。
Transl Res. 2022 Oct;248:68-86. doi: 10.1016/j.trsl.2022.06.002. Epub 2022 Jul 29.
3
Paclitaxel-Coated Balloons and Stents for Lower Extremity Peripheral Arterial Disease Interventions: A Regulatory Perspective for the Practicing Clinician.用于下肢外周动脉疾病干预的紫杉醇涂层球囊和支架：执业临床医生的监管视角
Mayo Clin Proc. 2020 Aug;95(8):1569-1573. doi: 10.1016/j.mayocp.2020.01.035.
本文引用的文献
1
ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine.美国心脏病学会适当使用标准工作组、美国心脏协会、心血管血管造影和介入学会、介入放射学会和血管医学学会 2018 年外周动脉介入适当使用标准：一份报告
J Am Coll Cardiol. 2019 Jan 22;73(2):214-237. doi: 10.1016/j.jacc.2018.10.002. Epub 2018 Dec 17.
2
Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.紫杉醇涂层球囊和支架在下肢股腘动脉中的应用死亡风险：随机对照试验的系统评价和荟萃分析。
J Am Heart Assoc. 2018 Dec 18;7(24):e011245. doi: 10.1161/JAHA.118.011245.
3
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2016 AHA/ACC 指南：下肢外周动脉疾病患者管理——美国心脏病学会/美国心脏协会实践指南工作组的报告。
Circulation. 2017 Mar 21;135(12):e726-e779. doi: 10.1161/CIR.0000000000000471. Epub 2016 Nov 13.
4
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.基于聚合物的缓释紫杉醇洗脱TAXUS支架的一年临床结果：TAXUS-IV试验
Circulation. 2004 Apr 27;109(16):1942-7. doi: 10.1161/01.CIR.0000127110.49192.72. Epub 2004 Apr 12.
5
Paclitaxel (taxol).紫杉醇（泰素）。
N Engl J Med. 1995 Apr 13;332(15):1004-14. doi: 10.1056/NEJM199504133321507.
Zotero 插件